Investigating how PD-L1 modifications affect cancer diagnosis and treatment
PD-L1 MODIFICATIONS IN CANCER DIAGNOSIS AND TREATMENT
['FUNDING_R01'] · BAYLOR COLLEGE OF MEDICINE · NIH-11048860
This study is looking at a protein called PD-L1 that helps cancer cells hide from the immune system, and it aims to find out how changes to this protein can help doctors better diagnose and treat cancer, ultimately leading to better treatments for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11048860 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of PD-L1, a protein that helps tumors evade the immune system, in cancer diagnosis and treatment. The study aims to explore how modifications to PD-L1 can influence its behavior in the tumor microenvironment and its interaction with T cells, which are crucial for fighting cancer. By examining the mechanisms behind PD-L1's function and its detection in tumors, the research seeks to improve diagnostic methods and therapeutic strategies for cancer patients. Patients may benefit from new insights that could lead to more effective immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who may benefit from immunotherapy and have tumors expressing PD-L1.
Not a fit: Patients with cancers that do not express PD-L1 or those who are not candidates for immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments and diagnostic tools that enhance patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting PD-L1 for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, YONG — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: LI, YONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy